Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Clinical and histopathological predictors of outcome in malignant meningioma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. WHO grade I meningiomas: classification-tree for prognostic factors of survival

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Skull base versus non-skull base meningioma surgery in the elderly

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Meningiomas: skull base versus non-skull base

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Living with the cerebellar mutism syndrome: long-term challenges of the diagnosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Introduction to the cerebellar mutism syndrome

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. The supplementary motor area syndrome and the cerebellar mutism syndrome: a pathoanatomical relationship?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

We investigated possible clinical and histopathological prognostic factors in a malignant meningioma cohort with comprehensive long-term population-based follow-up data. Twenty-four consecutive patients treated surgically for malignant meningioma at the Department of Neurosurgery and the Department of Pathology, Rigshospitalet, Copenhagen, Denmark, from December 2000 to March 2014 were retrospectively evaluated regarding progression-free survival (PFS) and overall survival (OS). Clinical parameters were recorded. All specimens underwent immunohistochemical analysis for Ki-67 and phosphohistone-H3 (PHH3). Prognostication was assessed with Cox proportional hazard regression analysis. The median follow-up was 46.1 months (range 0.7-150.7). The median progression-free survival was 16.5 months (95% CI 11.4-43.0) and the median overall survival was 46.6 months (95% CI 20.4-NA). Six patients were alive at the end of follow-up; two of these had not experienced a recurrence. No clinical parameter showed significant association with PFS or OS. Mitotic index (MI) was significantly associated with PFS and OS, and PHH3 MI with PFS. Immunohistochemical reactivity of Ki-67 > 10% was a negative predictor of PFS (HR 3.92, 95% CI 1.47-10.4, p = 0.0063) and OS (HR 3.35, 95% CI 1.12-10.1, p = 0.0313). The histological subgrouping of grade III meningioma into anaplastic and non-anaplastic revealed increased PFS for the latter (HR 4.57, CI 95% 1.32-15.7, p = 0.0164). We could not verify previous clinical parameters as prognostic factors in malignant meningioma. MI and the PHH3 MI were prognostic within WHO grade III meningiomas for PFS. An overall tumor staining of Ki-67 > 10% correlated with PFS and OS within grade III tumors.

OriginalsprogEngelsk
TidsskriftJournal of Neurosurgery
Vol/bind43
Udgave nummer2
Sider (fra-til)643-653
Antal sider11
ISSN0022-3085
DOI
StatusUdgivet - apr. 2020

ID: 58349149